634. Myeloproliferative Syndromes: Clinical and Epidemiological: Risk Stratification and Prognostication
Khalid Abu-Zeinah, Khalil Saadeh, Richard T. Silver, et al.
An unacceptably high excess mortality has been observed in MPN patients under the age of 60. It is higher than in patients over 60 years of age.
Tiziano Barbui, Arianna Ghirardi, Alessandra Carobbio, et al.
The IPSS score can be useful in conjunction with the JAK2 mutation in addition to assessing the risk of survival. It helps to identify patients at vascular risk and suggest suitable antithrombotic prophylaxis.
Giuseppe Gaetano Loscocco, Paola Guglielmelli, Carmela Mannarelli, et al.
AT and VT are associated with unique risk factors in patients with PV. This is illustrated by data with JAK2VF VAF as a strong independent predictor of future venous thrombosis in PV associated with the previous history of venous events.
Ayalew Tefferi, Giuseppe Gaetano Loscocco, Faiqa Farrukh, et al.
Elevated ANC and decreased ALC are age-independent risk factors for survival in ET. The present study has identified this and thus enables the development of a globally applicable, easy-to-use “triple-A” risk model based on age, ANC, and ALC. Decreased ALC also predicted fibrotic and leukemic progression. The observations of the study authors suggest a potential value for immune profiling as an additional prognostic tool in MPN.
Aaron T. Gerds, Ruben A. Mesa, John M. Burke, et al.
Increased HCT levels (> 45%) as well as leukocytes (> 11 × 109 / l) and PLT numbers (> 400 × 109 / l)) were each associated with an increased risk of TE. For more info see abstract.
Douglas Tremblay, Andrew Srisuwananukorn, Lukas Ronner, et al.
For more info see abstract.